Physician
Devaney, Jennifer
Devaney, Jennifer was paid $1.34M by Medicaid between Jan 2018 and Dec 2024, across 48 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 34% of everything it billed.
33Billing provider infoDEVANEY, JENNIFER
GRAYSLAKE, IL 60030
GRAYSLAKE, IL 60030
33aNPI1528056801assigned 10/11/2005
33bProvider typePediatric Adolescent Medicine Physician
28Total paid$1.34M
24GClaims28,683
24DCodes billed48
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatric Adolescent Medicine Physician providers in Illinois
Rank by total paid#4 of 44
Median peer was paid$65K
This provider vs. median21×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 3,682 | $147K | |
| 2019 | 3,819 | $158K | |
| 2020 | 4,828 | $185K | |
| 2021 | 6,027 | $261K | |
| 2022 | 4,679 | $270K | |
| 2023 | 3,239 | $187K | |
| 2024incomplete | 2,409 | $135K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 34% | 9,492 | 7,876 | $456K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 12% | 1,936 | 1,762 | $156K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 11% | 1,102 | 1,023 | $147K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 8.5% | 1,548 | 1,396 | $114K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 7.0% | 1,164 | 998 | $94K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 5.9% | 1,741 | 1,582 | $79K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 5.3% | 974 | 845 | $72K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.1% | 666 | 556 | $55K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.4% | 431 | 408 | $32K |
| 96160 | 1.6% | 1,423 | 1,239 | $21K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.2% | 961 | 820 | $16K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 202 | 165 | $13K |
36 more codes
| 90686 | <1% | 1,308 | $13K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 875 | $11K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 220 | $6K |
| 90734 | <1% | 401 | $6K | |
| 90651 | <1% | 249 | $5K | |
| 0072A | <1% | 124 | $5K | |
| 0001A | <1% | 117 | $5K | |
| 0071A | <1% | 117 | $5K | |
| 0002A | <1% | 103 | $4K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 118 | $4K |
| 80061 | Lipid panel | <1% | 407 | $3K |
| 90620 | <1% | 151 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 100 | $2K |
| 90670 | <1% | 215 | $2K | |
| 90716 | <1% | 98 | $2K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 94 | $2K |
| 85018 | <1% | 761 | $2K | |
| 90707 | <1% | 128 | $2K | |
| 82947 | <1% | 410 | $1K | |
| 90715 | <1% | 82 | $984.84 | |
| 0003A | <1% | 16 | $674.24 | |
| 99406 | <1% | 67 | $537.34 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 35 | $507.50 |
| 90647 | <1% | 66 | $462.06 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 16 | $405.36 |
| 90696 | <1% | 12 | $381.00 | |
| 90723 | <1% | 44 | $345.75 | |
| 90633 | <1% | 30 | $192.00 | |
| 90672 | <1% | 13 | $83.20 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 19 | $77.90 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 14 | $0.75 |
| 99072 | 0% | 479 | $0.00 | |
| 1033F | 0% | 62 | $0.00 | |
| 99177 | 0% | 16 | $0.00 | |
| 4000F | 0% | 62 | $0.00 | |
| 96161 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.